RxDoctor Payments Data

Sumul Raval, MD

Neurology · West Long Branch, NJNPI 1376526673

Payments from drug & device makers

$29,621in general payments, 2019–2025

Across 380 payments — averaging $77.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Biogen$11K
  • Pfizer$485
  • Novocure Inc.$382
  • Acadia Pharmaceuticals Inc$330
  • Teva Pharmaceuticals USA, Inc.$299
  • plus $4K from 54 others

What the payments were for

  • Speaking & faculty fees$12,56467%
  • Food & beverage$5,72131%
  • Education$3722%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)39$13,061
Biogen26$11,306
Pfizer36$485
Novocure Inc.18$382
Acadia Pharmaceuticals Inc32$330
Teva Pharmaceuticals USA, Inc.14$299
Novartis16$294
Eisai Inc.19$277
Boston Scientific3$275
ANI Pharmaceuticals, Inc.16$262
Lilly USA, LLC14$226
AstraZeneca(2 entities)15$218
UCB, Inc.11$166
Neurocrine Biosciences, Inc.6$110
CSL Behring4$107
Aucta Pharmaceuticals, Inc.7$96
Sumitomo Pharma America, Inc.6$96
Azurity Pharmaceuticals, Inc.5$86
Amgen5$78
Medtronic2$78
Sunovion Pharmaceuticals Inc.4$65
Servier Pharmaceuticals LLC4$64
Bristol Myers Squibb4$61
Tanabe Pharma America, Inc.4$57
EMD Serono, Inc.4$57
MDD US Operations, LLC4$55
Lundbeck LLC3$53
Upsher-smith Laboratories LLC3$52
Merck3$51
Catalyst Pharmaceuticals, Inc.3$50
Argenx US, Inc.3$49
Genentech USA, Inc.3$47
Mallinckrodt Enterprises LLC3$45
Springworks Therapeutics, Inc.2$43
Sanofi3$40
SK Life Science, Inc.2$39
Axsome Therapeutics, Inc.2$38
Vanda Pharmaceuticals Inc.2$36
Johnson & Johnson2$36
Avadel CNS Pharmaceuticals, LLC2$35
Life Molecular Imaging Ltd2$33
Alnylam Pharmaceuticals Inc.2$33
Supernus Pharmaceuticals, Inc.2$31
Mallinckrodt Hospital Products Inc.2$30
Adamas Pharmaceuticals, Inc.2$29
Takeda Pharmaceuticals U.S.A., Inc.1$26
Merz North America, Inc.1$24
Merz Pharmaceuticals, LLC1$19
Esperion Therapeutics, Inc.1$18
Amylyx Pharmaceuticals, Inc.1$18
Cumberland Pharmaceuticals, Inc.1$17
Jazz Pharmaceuticals Inc.1$16
Abbott1$16
Octapharma USA, Inc.1$15
Kyowa Kirin, Inc.1$15
Acorda Therapeutics, Inc1$14
Grifols USA, LLC1$14
Akcea Therapeutics, Inc.1$14
Helsinn Therapeutics (U.S.), Inc.1$12
Biohaven Pharmaceutical Holding Company Ltd.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,621 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$895,837
Medicare patients
1,765
Services billed
8,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin16$231,446
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$169,265
VumerityDiroximel Fumarate16$137,702
Kesimpta PenOfatumumab12$104,888
CopaxoneGlatiramer Acetate13$74,599
GammakedImmune Globul G/Gly/Iga Avg 4612$69,547
BriviactBrivaracetam36$50,881
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$50,003
BotoxOnabotulinumtoxina35$45,806
VimpatLacosamide22$44,246
RytaryCarbidopa/Levodopa49$39,964
UbrelvyUbrogepant29$33,762
QuliptaAtogepant20$32,503
NamzaricMemantine Hcl/Donepezil Hcl31$32,378
Nurtec OdtRimegepant Sulfate18$26,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$57$231,44616 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$26$169,26525 claims
AbbVieBotox, Ubrelvy, Qulipta, Namzaric, Savella$13,061$147,397127 claims
BiogenVumerity$11,306$137,70216 claims
UCB, Inc.Briviact, Vimpat, Neupro$166$118,00771 claims
Teva Pharmaceuticals USA, Inc.Copaxone$299$74,59913 claims
Grifols USA, LLCGamunex-C$14$50,00314 claims
PfizerNurtec Odt$485$26,15218 claims
MerckBelsomra$51$4,63411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in West Long Branch

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →